RxDoctor Payments Data

Oliver Phillips, MD

Neurology · Lebanon, NHNPI 1477082022

Payments from drug & device makers

What this record shows

This record is dominated by grants: $45,000 of the $49,604 with a category attached, or 90.7%. 4 manufacturers reported payments, led by Medtronic at 54.6% of the total. Reporting peaked in 2021 at $35,000 and has fallen 97.7% since, to $798 in 2025. Among neurology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$49,604in general payments, 2019–2025

Across 44 payments — averaging $1127.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$27K
  • Abbott$12K
  • Boston Scientific$11K
  • Teva Pharmaceuticals USA, Inc.$210

What the payments were for

  • Grants$45,00091%
  • Travel & lodging$3,3777%
  • Food & beverage$9872%
  • Education$2410%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic27$27,074
Abbott10$11,522
Boston Scientific5$10,798
Teva Pharmaceuticals USA, Inc.2$210

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,604 in reported general payments places this provider in the 95th percentile of 92 neurology providers in New Hampshire.

See all neurology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$114,606
Medicare patients
382
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine50$336,029
NuplazidPimavanserin Tartrate15$113,151
RytaryCarbidopa/Levodopa23$37,689
Carbidopa-LevodopaCarbidopa/Levodopa609$18,137
Propranolol Hcl ErPropranolol Hcl111$6,188
Carbidopa39$5,506
RivastigmineRivastigmine Tartrate66$4,936
Carbidopa-Levodopa ErCarbidopa/Levodopa109$4,446
Rivastigmine20$4,374
Primidone111$4,022
Rasagiline Mesylate29$3,964
Entacapone21$3,287
Gabapentin75$1,467
Midodrine Hcl20$1,208
Pregabalin41$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$210$336,02950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 neurology providers in New Hampshire.

Other neurology in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →